PeptiDream Inc. (4587.T)
JPY 1883.0
(-0.4%)
JPY 1883.0
(-0.4%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.29 Billion JPY | -79.17% |
| 2022 | 15.8 Billion JPY | 234.51% |
| 2021 | -11.74 Billion JPY | -64.3% |
| 2020 | -7.14 Billion JPY | -2.33% |
| 2019 | -6.98 Billion JPY | -1.95% |
| 2018 | -6.85 Billion JPY | -95.51% |
| 2017 | -3.5 Billion JPY | 46.54% |
| 2016 | -6.55 Billion JPY | 5.1% |
| 2015 | -6.9 Billion JPY | -17.51% |
| 2014 | -5.87 Billion JPY | -72.91% |
| 2013 | -3.4 Billion JPY | 38.98% |
| 2012 | -5.57 Billion JPY | -2330.97% |
| 2011 | -229.22 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.54 Billion JPY | 21.03% |
| 2024 Q1 | -5.76 Billion JPY | -274.99% |
| 2023 Q2 | 8.26 Billion JPY | -1.31% |
| 2023 Q3 | 5.33 Billion JPY | -35.45% |
| 2023 FY | 3.29 Billion JPY | -79.17% |
| 2023 Q4 | 3.29 Billion JPY | -38.3% |
| 2023 Q1 | 8.37 Billion JPY | -47.0% |
| 2022 Q4 | 15.8 Billion JPY | -4.43% |
| 2022 FY | 15.8 Billion JPY | 234.51% |
| 2022 Q3 | 16.53 Billion JPY | 8.28% |
| 2022 Q2 | 15.26 Billion JPY | 28.2% |
| 2022 Q1 | 11.9 Billion JPY | 201.39% |
| 2021 Q1 | -11.54 Billion JPY | -61.49% |
| 2021 Q4 | -11.74 Billion JPY | 4.0% |
| 2021 Q3 | -12.23 Billion JPY | -3.89% |
| 2021 FY | -11.74 Billion JPY | -64.3% |
| 2021 Q2 | -11.77 Billion JPY | -2.02% |
| 2020 Q3 | -7.83 Billion JPY | -7.01% |
| 2020 Q4 | -7.14 Billion JPY | 8.78% |
| 2020 FY | -7.14 Billion JPY | -2.33% |
| 2020 Q2 | -7.32 Billion JPY | -3.8% |
| 2020 Q1 | -7.05 Billion JPY | 0.0% |
| 2019 FY | -6.98 Billion JPY | -1.95% |
| 2019 Q3 | -8.29 Billion JPY | -21.07% |
| 2019 Q2 | -6.85 Billion JPY | -13.93% |
| 2019 Q1 | -6.01 Billion JPY | -33.88% |
| 2018 FY | -6.85 Billion JPY | -95.51% |
| 2018 Q4 | -4.49 Billion JPY | 19.76% |
| 2018 Q3 | -5.59 Billion JPY | -59.75% |
| 2018 Q2 | -3.5 Billion JPY | -3.89% |
| 2018 Q1 | -3.37 Billion JPY | 1.66% |
| 2017 Q3 | -3.95 Billion JPY | 39.7% |
| 2017 Q1 | -5.22 Billion JPY | 9.0% |
| 2017 FY | -3.5 Billion JPY | 46.54% |
| 2017 Q2 | -6.55 Billion JPY | -25.41% |
| 2017 Q4 | -3.43 Billion JPY | 13.21% |
| 2016 Q3 | -7.93 Billion JPY | -14.88% |
| 2016 FY | -6.55 Billion JPY | 5.1% |
| 2016 Q1 | -7.02 Billion JPY | -30.83% |
| 2016 Q2 | -6.9 Billion JPY | 1.7% |
| 2016 Q4 | -5.74 Billion JPY | 27.62% |
| 2015 Q2 | -5.87 Billion JPY | -8.66% |
| 2015 FY | -6.9 Billion JPY | -17.51% |
| 2015 Q4 | -5.37 Billion JPY | -6.86% |
| 2015 Q3 | -5.02 Billion JPY | 14.49% |
| 2015 Q1 | -5.41 Billion JPY | -19.42% |
| 2014 Q3 | -3.51 Billion JPY | -3.45% |
| 2014 FY | -5.87 Billion JPY | -72.91% |
| 2014 Q1 | -3.29 Billion JPY | 7.2% |
| 2014 Q4 | -4.53 Billion JPY | -28.81% |
| 2014 Q2 | -3.4 Billion JPY | -3.33% |
| 2013 Q4 | -3.54 Billion JPY | 35.25% |
| 2013 Q3 | -5.47 Billion JPY | 1.71% |
| 2013 Q2 | -5.57 Billion JPY | 0.0% |
| 2013 FY | -3.4 Billion JPY | 38.98% |
| 2012 FY | -5.57 Billion JPY | -2330.97% |
| 2011 FY | -229.22 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | -343.211% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 390.314% |
| GNI Group Ltd. | -17.93 Billion JPY | 118.357% |
| Linical Co., Ltd. | -4.46 Billion JPY | 173.757% |
| Trans Genic Inc. | -221.16 Million JPY | 1588.451% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 174.92% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 168.726% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | -129.641% |
| AnGes, Inc. | -3.79 Billion JPY | 186.683% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | 882.304% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 86.783% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | 760.838% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | 805.91% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 221.649% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 274.346% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 435.185% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 196.908% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 418.204% |
| Kidswell Bio Corporation | 343.58 Million JPY | -858.119% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 438.476% |
| Ribomic Inc. | -2.09 Billion JPY | 256.781% |
| SanBio Company Limited | -3.78 Billion JPY | 186.866% |
| Healios K.K. | -2.19 Billion JPY | 250.319% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 448.411% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 225.45% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 332.311% |
| StemRIM | -8.41 Billion JPY | 139.144% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 170.289% |
| FunPep Company Limited | -1.79 Billion JPY | 283.564% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 254.084% |
| Stella Pharma Corporation | -1.11 Billion JPY | 394.084% |
| TMS Co., Ltd. | -3.44 Billion JPY | 195.513% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 159.254% |
| Cuorips Inc. | -5.56 Billion JPY | 159.198% |
| K Pharma,Inc. | -3.26 Billion JPY | 200.783% |
| Takara Bio Inc. | -32.2 Billion JPY | 110.223% |
| ReproCELL Incorporated | -2.93 Billion JPY | 212.008% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | 598.062% |
| StemCell Institute Inc. | -2.83 Billion JPY | 216.048% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 259.315% |
| CellSeed Inc. | -2.01 Billion JPY | 263.614% |